Oxford, UK – 22 August 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a live Webinar on Thursday 6th September (3 pm BST) hosted by Dr Daniel Swan, Senior NGS Computational Biologist at OGT. Entitled “Exome sequencing and analysis strategies that deliver meaningful results”, the Webinar will provide insight and advice for optimising exome sequencing studies, taking advantage of the knowledge and experience routinely offered as part of OGT’s comprehensive Genefficiency™ exome sequencing and analysis service. The Webinar will be ideal viewing for any clinical or genomic researchers interested in learning how to best utilise the power offered by next generation sequencing analysis.
Exome sequencing is fast becoming the technique of choice to identify the novel genetic variations underpinning a variety of conditions, from rare diseases to cancer. However, effective study design and data analysis strategies are essential to ensure the delivery of meaningful results. The live Webinar will provide insight into running a successful exome sequencing project, including the advantages of exome sequencing, considerations for effective study design, crucial data analysis optimisation steps and effective analysis workflows for different sample types (e.g. rare disease, trios and cancer samples).
To register for the Webinar please visit the sign-up page on the OGT website. For more information about OGT’s targeted sequencing and other genome analysis services, go to www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Diagnostic Biomarkers: Utilising proprietary next generation technologies, OGT is building a rich patent-protected portfolio of promising biomarkers for early-stage cancer and autoimmune disease detection. The biomarker pipeline includes advanced programmes in colorectal cancer, prostate cancer and pancreatic cancer plus the autoimmune disease systemic lupus erythematosus (SLE). OGT is currently assessing partnership opportunities to commercialise these biomarker panels.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.